FTC Says Drugmakers Must Face AndroGel Antitrust Suit
By Christopher Crosby ( July 27, 2018, 4:58 PM EDT) -- The Federal Trade Commission on Thursday told a Georgia federal court that several pharmaceutical companies aren't entitled to a second chance to escape from a nearly decade-old antitrust suit alleging they conspired to keep a generic version of the testosterone drug AndroGel off the market, because such a "turducken task" would entail litigating patent validity. ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.